Safety and Tolerability of Donepezil with Solifenacin in Patients with Dementia of the Alzheimer's Type LONG TERM EXTENSION SAFETY STUDY IN PATIENTS WITH DEMENTIA OF THE ALZHEIMER'S TYPE WHO COMPLETED STUDY CPC-001-10
Martin Farlow, MD
Primary Investigator
Jessica MacLean
Primary Investigator
Overview
The purpose of this study is to evaluate the continued safety and tolerability of the maximum tolerated dose of donepezil as determined in Protocol CPC-001-07 when administered with solifenacin 20 mg/day and to evaluate whether the increased dose of solifenacin enables to safely further increase the maximum tolerated dose of donepezil.
Description
The purpose of this study is to evaluate the continued safety and tolerability of the maximum tolerated dose of donepezil as determined in Protocol CPC-001-07 when administered with solifenacin 20 mg/day and to evaluate whether the increased dose of solifenacin enables to safely further increase the maximum tolerated dose of donepezil.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Alzheimer's disease
-
Age: - 100 Years
-
Gender: All
